Effect of 50 mg enteric-coated aspirin (Astrix) on thromboxane and prostacyclin synthesis.
Although low-dose soluble aspirin can be recommended as a useful anti-thrombotic drug regimen in patients with vascular disease, enteric-coated preparations have a theoretical advantage for aspirin preparations which are to be ingested daily for many years. We have demonstrated that a 50 mg enteric-coated aspirin formulation (Astrix) which has an absorption rate much lower than soluble aspirin, is sufficient to inhibit platelet thromboxane synthesis while causing no major decrease in vascular prostacyclin synthesis.
James
M J
MJ
Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia.
Walsh
J A
JA
Foreman
R K
RK
D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D011464:Epoprostenol / Q000096:biosynthesis*; D005343:Fibrinolytic Agents; D006801:Humans; D013928:Thromboxane A2 / Q000096:biosynthesis*
D003692:Delayed-Action Preparations; D005343:Fibrinolytic Agents; D013928:Thromboxane A2; D011464:Epoprostenol; D001241:Aspirin